Internal Medicine, Rheumatology · Jefferson City, MO
NPI
1366428914
Since 2005
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1241 W Stadium Blvd
Jefferson City, MO, 65109
Phone (573) 635-5264
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.8M
242,382 services
Medicare patients, 2024
790
Average age 74
Drug cost, 2024
$4.8M
5,031 prescriptions
Company payments, 2025
$856
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Stephen D Sides was code J3380 (injection, vedolizumab, intravenous, 1 mg), 39,000 times for 19 patients. In total Stephen D Sides billed 242,382 services in 115 codes, and Medicare paid $3.8M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-08-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3380 Injection, vedolizumab, intravenous, 1 mg | Office | 39,000 | 19 | $17.41 | $679K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 35,800 | 34 | $9.04 | $324K |
| J0897 Injection, denosumab, 1 mg | Office | 27,001 | 277 | $20.26 | $547K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 14,275 | 20 | $33.81 | $483K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 5,440 | 22 | $24.57 | $134K |
| J9312 Injection, rituximab, 10 mg | Office | 3,503 | 12 | $61.22 | $214K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,386 | 29 | $0.22 | $311 |
| 36415 Venipuncture Blood Collection | Office | 994 | 367 | $8.60 | $8,549 |
| 85025 Blood Count | Office | 818 | 326 | $7.55 | $6,177 |
| 85652 Clinical Chemistry | Office | 792 | 322 | $2.63 | $2,082 |
| 80053 Clinical Chemistry | Office | 754 | 309 | $10.26 | $7,739 |
| 96365 Intravenous Infusion, Hydration | Office | 716 | 132 | $42.31 | $30K |
| 96372 Injection Administration | Office | 682 | 294 | $10.26 | $6,999 |
| 99214 Office E&M - Established | Office | 622 | 357 | $81.05 | $50K |
| 96415 Chemotherapy Administration | Office | 298 | 45 | $18.04 | $5,377 |
By year: 2022 $3.2M for 216,106 services; 2023 $3.6M for 211,508 services; 2024 $3.8M for 242,382 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 994 | 367 | $8.60 | $8,549 |
| 85025 Blood Count | 818 | 326 | $7.55 | $6,177 |
| 85652 Clinical Chemistry | 792 | 322 | $2.63 | $2,082 |
| 80053 Clinical Chemistry | 754 | 309 | $10.26 | $7,739 |
| 86140 Clinical Chemistry | 52 | 39 | $5.01 | $260 |
| 80048 Clinical Chemistry | 48 | 47 | $8.29 | $398 |
| 82550 Clinical Chemistry | 45 | 44 | $6.38 | $287 |
| 86431 Immunoassay | 36 | 36 | $5.56 | $200 |
| 86200 Immunoassay | 36 | 36 | $12.69 | $457 |
| 87340 Immunoassay | 30 | 30 | $10.12 | $304 |
Medicare prescription drug claims, 2024
In 2024, the drug Stephen D Sides prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 1,043 prescriptions and refills. In total Stephen D Sides wrote 5,031 Medicare prescriptions that cost $4.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 1,043 | 1,908 | 210 | $35K |
| Methotrexate Methotrexate Sodium | 937 | 1,880 | 196 | $25K |
| Prednisone Generic | 844 | 1,377 | 202 | $5,282 |
| Celecoxib Generic | 234 | 368 | 51 | $5,635 |
| Folic Acid Generic | 148 | 317 | 32 | $1,251 |
| Leflunomide Generic | 126 | 208 | 26 | $5,347 |
| Meloxicam Generic | 122 | 241 | 28 | $514 |
| Enbrel Sureclick Etanercept | 107 | 125 | 13 | $928K |
| Allopurinol Generic | 103 | 223 | 21 | $1,420 |
| Humira(Cf) Pen Adalimumab | 92 | 131 | 14 | $987K |
| Potassium Chloride Generic | 88 | 153 | 23 | $1,261 |
| Nabumetone Generic | 77 | 103 | 20 | $1,286 |
| Mycophenolate Mofetil Generic | 67 | 87 | 12 | $7,396 |
| Gabapentin Generic | 53 | 85 | 11 | $710 |
| Otezla Apremilast | 53 | 61 | Under 11 | $294K |
Brand drugs: - claims; generic drugs: 4,401 claims; opioid claims: 13.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Stephen D Sides $856 ($856 in general payments such as food, travel and fees) from 18 companies. The largest payer was Amgen Inc. with $209.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 19 | $209 |
| Janssen Biotech, Inc. JNJ | 10 | $191 |
| Novo Nordisk Inc NVO | 4 | $64.07 |
| Dexcom, Inc. DXCM | 2 | $48.48 |
| Pfizer Inc. PFE | 2 | $45.76 |
| Merck Sharp & Dohme LLC MRK | 2 | $39.84 |
| Xeris Pharmaceuticals, Inc. | 2 | $38.65 |
| GlaxoSmithKline, LLC. GSK | 2 | $30.29 |
| Vertex Pharmaceuticals Incorporated VRTX | 1 | $28.15 |
| Medtronic, Inc. MDT | 1 | $26.35 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.